705
Participants
Start Date
March 31, 2006
Primary Completion Date
December 31, 2007
Study Completion Date
August 31, 2008
Botulinum Toxin Type A
Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
placebo (saline)
Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
Walnut Creek
Calgary
Zagreb
Essen
Zurich
London
Lead Sponsor
Allergan
INDUSTRY